Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

481 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Low frequency mutations in ribosomal proteins RPL10 and RPL5 in multiple myeloma.
Hofman IJF, Patchett S, van Duin M, Geerdens E, Verbeeck J, Michaux L, Delforge M, Sonneveld P, Johnson AW, De Keersmaecker K. Hofman IJF, et al. Among authors: delforge m. Haematologica. 2017 Aug;102(8):e317-e320. doi: 10.3324/haematol.2016.162198. Epub 2017 Apr 20. Haematologica. 2017. PMID: 28428269 Free PMC article. No abstract available.
Thalidomide in induction treatment increases the very good partial response rate before and after high-dose therapy in previously untreated multiple myeloma.
Lokhorst HM, Schmidt-Wolf I, Sonneveld P, van der Holt B, Martin H, Barge R, Bertsch U, Schlenzka J, Bos GM, Croockewit S, Zweegman S, Breitkreutz I, Joosten P, Scheid C, van Marwijk-Kooy M, Salwender HJ, van Oers MH, Schaafsma R, Naumann R, Sinnige H, Blau I, Delforge M, de Weerdt O, Wijermans P, Wittebol S, Duersen U, Vellenga E, Goldschmidt H; Dutch-Belgian HOVON; German GMMG. Lokhorst HM, et al. Among authors: delforge m. Haematologica. 2008 Jan;93(1):124-7. doi: 10.3324/haematol.11644. Haematologica. 2008. PMID: 18166796 Free article. Clinical Trial.
A randomized phase 3 study on the effect of thalidomide combined with adriamycin, dexamethasone, and high-dose melphalan, followed by thalidomide maintenance in patients with multiple myeloma.
Lokhorst HM, van der Holt B, Zweegman S, Vellenga E, Croockewit S, van Oers MH, von dem Borne P, Wijermans P, Schaafsma R, de Weerdt O, Wittebol S, Delforge M, Berenschot H, Bos GM, Jie KS, Sinnige H, van Marwijk-Kooy M, Joosten P, Minnema MC, van Ammerlaan R, Sonneveld P; Dutch-Belgian Hemato-Oncology Group (HOVON). Lokhorst HM, et al. Among authors: delforge m. Blood. 2010 Feb 11;115(6):1113-20. doi: 10.1182/blood-2009-05-222539. Epub 2009 Oct 30. Blood. 2010. PMID: 19880501 Free article. Clinical Trial.
The t(14;20)(q32;q12): a rare cytogenetic change in multiple myeloma associated with poor outcome.
Vekemans MC, Lemmens H, Delforge M, Doyen C, Pierre P, Demuynck H, Bries G, Lemmens J, Meeus P, Straetmans N, Bauwens D, Vidrequin S, Rack K, Vandenberghe P, Wlodarska I, Michaux L. Vekemans MC, et al. Among authors: delforge m. Br J Haematol. 2010 Jun;149(6):901-4. doi: 10.1111/j.1365-2141.2010.08113.x. Epub 2010 Feb 9. Br J Haematol. 2010. PMID: 20148877 Free article. Review. No abstract available.
Multiple myeloma treatment strategies with novel agents in 2011: a European perspective.
Ludwig H, Beksac M, Bladé J, Cavenagh J, Cavo M, Delforge M, Dimopoulos M, Drach J, Einsele H, Facon T, Goldschmidt H, Harousseau JL, Hess U, Kropff M, Leal da Costa F, Louw V, Magen-Nativ H, Mendeleeva L, Nahi H, Plesner T, San-Miguel J, Sonneveld P, Udvardy M, Sondergeld P, Palumbo A. Ludwig H, et al. Among authors: delforge m. Oncologist. 2011;16(4):388-403. doi: 10.1634/theoncologist.2010-0386. Epub 2011 Mar 26. Oncologist. 2011. PMID: 21441574 Free PMC article. Review.
Management of treatment-emergent peripheral neuropathy in multiple myeloma.
Richardson PG, Delforge M, Beksac M, Wen P, Jongen JL, Sezer O, Terpos E, Munshi N, Palumbo A, Rajkumar SV, Harousseau JL, Moreau P, Avet-Loiseau H, Lee JH, Cavo M, Merlini G, Voorhees P, Chng WJ, Mazumder A, Usmani S, Einsele H, Comenzo R, Orlowski R, Vesole D, Lahuerta JJ, Niesvizky R, Siegel D, Mateos MV, Dimopoulos M, Lonial S, Jagannath S, Bladé J, Miguel JS, Morgan G, Anderson KC, Durie BG, Sonneveld P. Richardson PG, et al. Among authors: delforge m. Leukemia. 2012 Apr;26(4):595-608. doi: 10.1038/leu.2011.346. Epub 2011 Dec 23. Leukemia. 2012. PMID: 22193964 Review.
Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial.
Miguel JS, Weisel K, Moreau P, Lacy M, Song K, Delforge M, Karlin L, Goldschmidt H, Banos A, Oriol A, Alegre A, Chen C, Cavo M, Garderet L, Ivanova V, Martinez-Lopez J, Belch A, Palumbo A, Schey S, Sonneveld P, Yu X, Sternas L, Jacques C, Zaki M, Dimopoulos M. Miguel JS, et al. Among authors: delforge m. Lancet Oncol. 2013 Oct;14(11):1055-1066. doi: 10.1016/S1470-2045(13)70380-2. Epub 2013 Sep 3. Lancet Oncol. 2013. PMID: 24007748 Clinical Trial.
Expert panel consensus statement on the optimal use of pomalidomide in relapsed and refractory multiple myeloma.
Dimopoulos MA, Leleu X, Palumbo A, Moreau P, Delforge M, Cavo M, Ludwig H, Morgan GJ, Davies FE, Sonneveld P, Schey SA, Zweegman S, Hansson M, Weisel K, Mateos MV, Facon T, Miguel JF. Dimopoulos MA, et al. Among authors: delforge m. Leukemia. 2014 Aug;28(8):1573-85. doi: 10.1038/leu.2014.60. Epub 2014 Feb 5. Leukemia. 2014. PMID: 24496300 Free PMC article. Review.
European perspective on multiple myeloma treatment strategies in 2014.
Ludwig H, Sonneveld P, Davies F, Bladé J, Boccadoro M, Cavo M, Morgan G, de la Rubia J, Delforge M, Dimopoulos M, Einsele H, Facon T, Goldschmidt H, Moreau P, Nahi H, Plesner T, San-Miguel J, Hajek R, Sondergeld P, Palumbo A. Ludwig H, et al. Among authors: delforge m. Oncologist. 2014 Aug;19(8):829-44. doi: 10.1634/theoncologist.2014-0042. Epub 2014 Jul 25. Oncologist. 2014. PMID: 25063227 Free PMC article. Review.
481 results